GlassScriptPhysician profile
Elizabeth Sha Duque
NPI 1568105492
$1,357.31
in general payments reported to CMS, 2019-2025
14 companies · $214 in 2025
The $214 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $215 · 2023: $357 · 2024: $572 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,142.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $445.36 | 2022-2025 | |
| Pfizer INC. | $171.08 | 2023-2025 | |
| Gilead Sciences, INC. | $127.09 | 2023-2024 | |
| Ardelyx, INC. | $116.34 | 2022-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.17 | 2023-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $64.07 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $56.41 | 2025 | Rezdiffra |
| Ferring Pharmaceuticals INC. | $44.81 | 2023 | Rebyota, Clenpiq |
| Intercept Pharmaceuticals, INC. | $44.19 | 2022-2023 | Ocaliva |
| Braintree Laboratories, INC. | $43.43 | 2022-2024 | Suflave |
| Aimmune Therapeutics, INC. | $42.67 | 2024-2025 | Zenpep |
| Genzyme Corporation | $41.08 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.01 | 2022-2023 | Entyvio |
| Ironwood Pharmaceuticals, INC | $31.60 | 2023 | Linzess |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Duque listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.